Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program

by: Iola Bonggay

The Food and Drug Administration, otherwise referred to as FDA, is a federal government agency operating within the United States Department of Health and Human Services that is primarily responsible for protecting and promoting public health through the regulation and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs.

The grants and programs of the FDA are all geared towards the achievement of its primary agency mission which is to "protect consumers and enhance public health by maximizing compliance of FDA regulated products and minimizing risk associated with those products."

In this capacity, the Food and Drug Administration has recently established the Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program in an attempt to study the effects of various physicochemical properties of ophthalmic suspensions and emulsions on ocular bioavailability.

To this effect, the program will cover the key physicochemical properties which may impact clearance, distribution, and drug release; specifically globule/particle size distribution, surface change, osmolality, pH, viscosity, and dispersibility.

It is known that there are several kinds of opthalmic drugs which are available in the market today. The goal of this study is to determine which manufacturing differences may result in physicochemical differences which in turn may affect clearance, distribution, and release of the drug.

  (continued...)

Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program
  Page 2

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Health Resources and Services Administration: HIV Care Grant Program, Part B
Part B of the HIV Care Grant Program is designed to develop or improve the people's access to a comprehensive continuum of high-quality, community-based care for low-income patients diagnosed with HIV.

---

Strategic Alliances for Medications Development to Treat Substance Use Disorder Program
The National Institutes of Health, in cooperation with the National Institute on Drug Abuse (NIDA), has recently established the Strategic Alliances for Medications Development to Treat Substance Use Disorder Program wherein both agencies seek to support the development of substance abuse drugs by leveraging the strengths of two or more organizations toward a common goal of medications development.

---

International Research Collaboration on Drug Abuse and Addiction
The National Institutes of Health, in collaboration with the National Institute on Drug Abuse (NIDA), has recently established the International Research Collaboration on Drug Abuse and Addiction Program wherein they seek to solicit collaborative research applications regarding addiction and drug use, through the utilization of special opportunities and resources that exist outside the United States of America.

---

Excellence in Hemoglobinopathies Research Award Program
The National Institutes of Health has formed a collaboration with the National Heart, Lung, and Blood Institute (NHLBI) in an effort to establish the Excellence in Hemoglobinopathies Research Award Program wherein both agencies have agreed to financially support the creation of studies that could potentially improve high-impact multi-disciplinary basic and translational research studies in the hemoglobinopathies.

---